Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ:SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with fibromyalgia and chronic pain as the initially targeted indications.
发育阶段的迷幻生物技术 筒仓制药 纳斯达克股票代码：SILO）已签订一项研发协议，研究和开发一种以纤维肌痛和慢性疼痛为初始靶向适应症的剂量和延时释放氯胺酮植入物。
The new project includes analytical testing and small batch, preclinical proof-of-concept trials to determine drug release and stability.
新项目包括分析测试和小批量临床前概念验证试验，以确定药物的释放和稳定性。
CEO Eric Weisblum says the company is "beginning to explore" the option of treating fibromyalgia through ketamine-loaded implants, which would add to the existent R&D program of novel compound SP-26.
首席执行官埃里克·韦斯布鲁姆 表示，该公司正在 “开始探索” 通过装有氯胺酮的植入物治疗纤维肌痛的选择，这将增加现有的新化合物 SP-26 的研发计划。
The latter development is a time-released, dosage-controlled ketamine formulation of which positive results for pre-IND-enabling studies were recently announced, and for which Silo has filed a provisional patent application this past March.
后一项开发是一种定时发布、剂量控制的氯胺酮配方，该配方最近宣布了其促成前IND研究的积极结果，Silo已于去年3月为此申请了临时专利申请。
Weisblum believes the results from the new research will provide additional information and data for Silo's ongoing studies of ketamine treatments for fibromyalgia and other chronic pain conditions.
Weisblum认为，这项新研究的结果将为Silo正在进行的氯胺酮治疗纤维肌痛和其他慢性疼痛疾病的研究提供更多信息和数据。
Fibromyalgia, a chronic condition causing generalized musculoskeletal pain as well as memory issues, sleep problems and fatigue affects about four million American adults -or about 2% of the total adult population.
纤维肌痛是一种导致全身性肌肉骨骼疼痛以及记忆问题、睡眠问题和疲劳的慢性疾病，影响着大约四百万美国成年人，约占成年人口总数的2％。
An analysis by Fortune Business Insights has estimated the treatment market for this condition is projected to grow at a CAGR of over 9% within the 2020-2027 period, while a more recent review by EMR calculated an expected 8.1% CAGR for the period spanning 2023-2031, achieving a $5.27 million global value by 2031.
的分析 《财富》商业洞察 估计，在2020-2027年期间，这种疾病的治疗市场预计将以超过9％的复合年增长率增长，而EMR最近的一项审查计算，在2023-2031年期间，预计复合年增长率为8.1％，到2031年全球价值将达到527万美元。
See also: Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific
另见：Wesana 股东投票支持向露西科学出售 psilocybin 和 CBD Therapy 资产
Silo is not alone in targeting fibromyalgia with psychedelic-assisted therapy. Tryp Therapeutics (OTC:TRYPF) is a patent-applied and in-progress psilocybin-based novel treatment.
Silo并不是唯一一个通过迷幻药辅助疗法靶向纤维肌痛的公司。Tryp Therapeutics（OTC: TRYPF）是一种已申请专利且正在进行中的基于psilocybin的新型疗法。
Photo: Benzinga edit with photo by geralt on Pixabay and Wikimedia Commons.
照片：Benzinga 在 Pixabay 和维基共享资源上编辑了由 geralt 拍摄的照片。
译文内容由第三方软件翻译。